Company Overview

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm, and a multinational manufacturer of medical devices. These devices are used in interventional medical specialties such as interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Boston Scientific produces less invasive medical devices designed to be inserted into the human body through small openings or cuts. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for approximately 36% of the firm's total sales.

Business Segments

Boston Scientific operates through two primary segments:

MedSurg Segment

The MedSurg segment encompasses Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions using less-invasive technologies.

Cardiovascular Segment

The Cardiovascular segment includes Cardiology and Peripheral Interventions. The company is notably recognized for the development of the Taxus Stent, a drug-eluting stent used to open clogged arteries.

Key Products and Technologies

The company manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence.

Financial Performance

The company has demonstrated strong financial performance with consistent double-digit revenue growth across both its major business segments.

Full Year 2024 Results

- Revenue: For the full year 2024, the company generated net sales of $16.747 billion, growing 17.6% on a reported basis, 18.5% on an operational basis, and 16.4% on an organic basis.

- Net Income: The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion ($1.25 per share), compared to $1.570 billion ($1.07 per share) a year ago.

- Growth: In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.

Q4 2024 Results

- Revenue: Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4% on a reported basis, 23.1% on an operational basis, and 19.5% on an organic basis, all compared to the prior year period.

- Earnings: The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million ($0.38 per share - EPS), compared to $504 million ($0.34 per share) a year ago. Adjusted EPS for the period was $0.70, compared to $0.55 a year ago.

Q3 2024 Results

- Revenue: Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4% on a reported basis, 19.5% on an operational basis, and 18.2% on an organic basis, all compared to the prior year period.

- Earnings: The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million ($0.32 per share - EPS), compared to $505 million ($0.34 per share) a year ago. Adjusted EPS for the period was $0.63, compared to $0.50 a year ago.

Market Position and Valuation

- Market Capitalization: $155.07 Billion USD (as of August 2025).

- Ranking: This valuation places Boston Scientific as the world's 105th most valuable company according to our data.

- Category: A market capitalization between $10 billion and $200 billion categorizes BSX within the large capitalization segment.

Boston Scientific is a global leader in medical devices, excelling in both its MedSurg and Cardiovascular segments with consistent, industry-beating growth.

Stock Performance

Boston Scientific (NYSE: BSX) has experienced a stock price increase of over 30% in the last twelve months, significantly outperforming the S&P 500's gain of 9%. According to 22 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price target is $118.91, representing an anticipated increase of 20.14% from the latest price.

Leadership

Mike Mahoney serves as Chairman and Chief Executive Officer of Boston Scientific. Under his leadership, the company has achieved sustained high performance, which Mahoney attributes to "the strength of our talented global team, differentiated portfolio and category leadership strategy."

Innovation and Competitive Position

Boston Scientific remains one of the top players in intellectual property within the medical technology arena, positioning it well for continued innovation and competitiveness against rivals. The company is considered a 'forever stock' due to its management's foresight, robust research and development efforts, and leadership in areas such as AI-driven medical devices.

Boston Scientific continues to demonstrate strong financial performance, with consistent double-digit revenue growth across its major business segments, solidifying its position as a leader in the global medical device industry through a comprehensive portfolio of innovative healthcare solutions.